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ABSTRACT  
Objectives: To determine the coverage rate of hepatitis B virus (HBV) vaccine and to evaluate the immune 
response to HBV vaccine by measuring hepatitis B surface antibody (anti-HBs) among malnourished un-
der-five-year old children. 
Methods: A cross-sectional study was conducted in two tertiary hospitals in Yemen; Al-Sabeen Maternity 
and Child Hospital in Sana’a and the Yemeni-Swedish Hospital in Taiz city in the period from March 2014 
to Dec. 2014. The target population was malnourished children aged from 6 to 59 months old with a histo-
ry of three HBV vaccine doses in infancy. According to the World Health Organization’s definition of malnu-
trition, 121 malnourished children were enrolled in the study. Data of malnourished children were collect-
ed using a pre-designed, pre-tested questionnaire. Two milliliters of venous blood were taken, and anti-
HBs was then tested by enzyme linked immunosorbent assay. An anti-HBs level of at least 10 IU/L was 
considered a successful response to the vaccine. 
Results: The coverage rate of HBV vaccine among malnourished children was 89.3%, being higher among 
girls (52.1%) than boys (37.2%). Response to HBV vaccine (≥10 IU/L) was observed in 72.2% (78/108) of 
children while 27.8% (30/108) of children failed to respond to the vaccine, with a statistically significant 
difference (p <0.001). 
Conclusions: A good HBV vaccine coverage rate was found among malnourished Yemeni children, with a 
moderate rate of protection. Therefore, re-vaccination or administration of booster doses to a substantial 
proportion of vaccinated children should be considered. 
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1. Introduction 
Hepatitis B virus (HBV) infection poses a major 
health problem worldwide, with about a third 
of the world’s population showing seropositivi-
ty as a result of current or previous infections. 
Approximately 400 million people are chroni-
cally infected with the virus worldwide, leading 
to about one million annual deaths from liver 
cirrhosis and hepatocellular carcinoma (1). 
Several previous surveys in Yemen showed 
high prevalence rates of hepatitis B surface an-
tigen (HBsAg) ranging from 8% to 50% (2, 3). 
HBsAg prevalence rates were reported to be 
26.3%, 10.5%, 5.6% and 4.8% in Socotra, 
Sana'a, Hajjah and Aden, respectively during 
the period from 2000 to 2005 (4). Chronic HBV 
infection develops among 90% of newborns, 
29–40% of children (1–5 years old) and 5–10% 
of adults (5). 
Primary prevention by vaccination is the 
most effective way for controlling HBV spread 
(6). Given that HBV vaccine has been available 
since 1982, the incidence of HBV infection and 
its associated morbidity and mortality declined 
in Taiwan and the United States (7, 8). In 1998, 
the World Health Organization (WHO) recom-
mended the inclusion of HBV vaccine in the Na-
tional Immunization Programme of Yemen, par-
ticularly among neonates, where vertical 
transmission is common, irrespective of the 
HBsAg prevalence (9). Injection of three doses 
of HBV vaccine provides a safe level of protec-
tion in 95% of infants and healthy children. 
However, the primary immune response to HBV 
vaccine decreases with increasing age, especial-
ly after 40 years old, where it may decline to 
90% (10). Studies in Yemen have demonstrated 
the immunogenicity of HBV vaccine among 
healthy infants and children, where between 
54.8% (9) and 83.5% (11) showed a good anti-
HBs response to the pentavalent or single vac-
cine of ≥10 IU/L. Several factors are associated 
with decreased immune response to the vac-
cine, including increasing age, obesity, sex as 
well as genetic factors. Nutritional status is a 
major factor influencing both the immune re-
sponse and immunodeficiency (12, 13). In de-
veloping countries, about a third of children 
suffer from malnutrition (15), and malnutrition 
has been reported as one of the most significant 
causes of mortality, especially among under 
five-year-old children (14). Malnutrition is ac-
countable for more than 50% of the 10.8 mil-
lion deaths per year among under five-year-old 
children and causes a death per second associ-
ated with infectious diseases in developing 
countries (16). Yemen has one of the highest 
under-five mortality rates in the world, with 77 
deaths per 1,000 live births. Fifty four percent 
of child mortality is associated with under-
weight. Additionally, it has the second highest 
chronic malnutrition rate among children after 
Afghanistan (17).  
Causes of malnutrition in Yemen include 
improper complementary food preparation, 
low economic status, lack of nutritional 
knowledge, illiteracy, lack of clean water sup-
plies, early or delay in weaning and dependence 
on imported grains as the main staple (18). 
Malnutrition and food insecurity are further 
aggravated by conflicts in the country (18). 
Malnutrition may affect a variety of immune 
cells that may therefore be indicative of the nu-
tritional status (19).  
Defects in cellular and humoral immunity as 
well as phagocyte function disorders can be 
caused by protein energy malnutrition (PEM) 
(20, 21). In addition, reductions in the levels of 
the complement (except C4), secretory immu-
noglobulin A and cytokines can result (20, 21). 
Malnutrition, secondary to deficiencies in pro-
teins, metal elements or vitamins, can lead to 
changes and severe atrophy in the thymus 
gland because of apoptosis-induced thymocyte 
depletion. This can lead to a persistent lympho-
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cyte reduction, particularly in the immature 
CD4þ CD8þ cells, and to a decrease in cell pro-
liferation. It is noteworthy that these conditions 
can be reversed following proper diet rehabili-
tation (22). PEM also reduces the concentra-
tions of IgA, IgM and IgG and the production of 
cytokines (23). PEM-associated micronutrient 
deficiencies also have adverse effects on the 
immune response. Deficiency in zinc, iron, cop-
per, vitamins plays an important role in re-
duced immune response as a result of malnutri-
tion (24). Zinc, copper and selenium are needed 
to maintain and reinforce immune and antioxi-
dant systems (25). Vitamin A stimulates cell 
differentiation and cytokine secretion by mac-
rophages, including tumor necrosis factor, in-
terleukin (IL)-1, IL-6, and IL-12 (26).  
The present study aimed to determine the 
coverage rate of HBV vaccine among malnour-
ished Yemeni children and to assess the im-
mune response of those vaccinated with three 
doses of HBV vaccine by measuring the circulat-
ing anti-HBs levels. 
 
2. Methods 
2.1. Study population 
A cross-sectional study was conducted in 
Al-Sabeen Maternity and Child Hospital in 
Sana'a and in the Yemeni-Swedish Hospital in 
Taiz, Yemen, in the period from March 2014 to 
Dec. 2014. The study was approved by the De-
partment of Immunology, Tropical Medicine 
Program in Sudan Academy of Sciences, Sudan. 
Informed consent was obtained from the par-
ents or guardians of children following explana-
tion of the study goals.  
The enrolled children were evaluated for 
the type and degree of malnutrition by anthro-
pometric measurements, including body 
weight, height, and mid-upper-arm circumfer-
ence (MUAC) in relation to age using regularly 
validated, standard equipment. The weights 
were measured by scales to the nearest 10 
grams and the length/height to the nearest cen-
timeter. Three indicators were used to assess 
the nutritional status of children: weight-for-
length, length-for-age and weight-for-age scales 
are ≤–2 standard deviation (SD) child is at 
moderate and ≤–3 SD is at severe malnutrition 
(27). Based on the WHO classification of malnu-
trition (27), 121 malnourished children were 
enrolled in the study and classified into two 
groups: moderate and severe malnutrition. 
Children’s data were collected in a pre-
designed, pre-tested questionnaire, including 
vaccination dates according to the last dose of 
HBV vaccine, sex and age at the time of the 
study. 
2.2. Measurement of HBV markers 
Blood samples were collected from selected 
malnourished children, aged from 6 to 59 
months old, having taken the three doses of the 
pentavalent HBV vaccine at 6, 10 and 14 weeks 
of age, according to the WHO recommenda-
tions. Two milliliters of venous blood were col-
lected, and sera were separated and frozen at –
20 °C until testing. All samples were investigat-
ed for anti-HBs using a fully-automated enzyme 
linked immunosorbent assay (ELISA) (AxSYM, 
Abbott, Germany). Anti-HBs antibodies were 
detected by sandwich ELISA using recombinant 
HBsAg according to the manufacturer’s instruc-
tions.  
HBsAg and hepatitis B core antibody (anti-
HBc) were measured to differentiate current 
from previous infections, where all anti-HBc-
positive individuals were excluded. Anti-HBs 
antibodies were expressed in international 
units per liter (IU/L). The protective immune 
response was defined as anti-HBs antibody lev-
els of more than 10 IU/L (28, 29). The results 
were classified into four groups as follows: no 
response if anti-HBs level was <10 IU/L, low 
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response if anti-HBs level was 10–100 IU/L, 
good response if anti-HBs level was 101–1000 
IU/L and high response if anti-HBs level was 
>1000 IU/L. 
2.3. Statistical analysis 
The data were analyzed using the Statistical 
Package for Social Sciences (SPSS) version 17 
(SPSS Inc., Chicago, IL, USA). For qualitative da-
ta, chi-square test was used. Differences were 
considered statistically significant at p values 
<0.05. 
 
3. Results 
A total of 121 malnourished children with a 
mean age of 23.11 ± 16.8 months were included 
in this study; 42.1% (51/121) were boys and 
57.9% (70/121) were girls. Vaccinated children 
represented 89.3% (108/121) of malnourished 
children, and the HBV vaccine coverage rate 
was higher (52.1%) among girls than boys 
(37.2%) (Table 1). In addition, 72.2% (78/108) 
of vaccinated children were responders (anti-
HBs level ≥10 IU/L) while 27.8% (30/108) 
were non-responders (anti-HBs levels <10 
IU/L). The average protective rate in all age 
group was 72.2%, with a significantly higher 
rate (p = 0.001) among younger age groups 
(Table 2). The age group of less than one year 
showed significantly higher anti-HBs levels 
than the age group of 4-5 years (p <0.001) (Ta-
ble 3). Of the vaccinated children, 41.7% 
(45/108) had moderate malnutrition and 
58.3% (68/108) had severe malnutrition. Sero-
protection was found among 72.2% (78/108) 
of vaccinated children. Protective rates in chil-
dren with moderate and severe malnutrition 
were 24.1% and 48.1%, respectively, with a 
statistically significant difference (p   = 0.043) 
)Table 4). 
Table 1. The HBV vaccine coverage rate among malnourished 
children according to sex 
Status 
Boys 
(n=51) 
Girls 
(n=70) 
Total 
(n=121) 
p value* 
No.(%) No. (%) No. (%) 
Vaccinated 45 (37.2) 63 (52.1) 108 (89.3) 
0.700 
Non-
vaccinated 
6 (5.0) 7 (5.8) 13 (10.7) 
Total 51 (42.1) 70 (57.9) 121 (100) 
* Calculated for chi-square 
Table 2. Comparison of anti-HBs antibody levels among malnour-
ished children according to age  
Age group 
(years) 
Anti-HBs 
˂10 IU/L 
Anti-HBs 
≥10 IU/L  
Total 
 
p value* 
No. (%) No. (%) 
˂1 5 (13.9) 31 (86.1) 36 0.023 
1–2 11 (25.0) 33 (75.0) 44 0.593 
>2–3 2 (25.0) 6 (75.0) 8 0.850 
>3–4 2 (28.6) 5 (71.4) 7 0.960 
4–5 10 (76.9) 3 (23.1) 13 <0.001 
Total 30 (27.8) 78 (72.2) 108 <0.001 
* Calculated for chi-square 
Table 3. Comparison of anti-HBs antibody levels between less 
than one-year-old and more than one-year-old malnourished 
children in Sana'a (2014) 
Age group 
(years) 
Anti-HBs 
˂10 IU/L 
Anti-HBs 
≥10 IU/L  
Total 
 
p value* 
No. (%) No. (%) 
˂1  5 (13.9) 31 (86.1) 36 
<0.001 4–5  10 (76.9) 3 (23.1) 13 
Total 15 (30.6) 78 (72.2) 49 
* Calculated for chi-square 
Table 4. Anti-HBs levels among vaccinated malnourished chil-
dren in Sana'a (2014) according to malnutrition severity 
Anti-HBs 
level 
(IU/L) 
Malnutrition severity 
 
Total 
No. (%) 
p value* 
Severe acute 
malnutrition 
No.(%) 
Moderate acute 
malnutrition 
No.(%) 
˂10 11 (10.2) 19 (17.6) 30(27.8) 
0.043 
10–100 21 (19.4) 11 (10.2) 32 (29.6) 
101–1000 19 (17.6) 10 (9.3) 29 (26.9) 
>1000 12 (11.1) 5 (4.6) 17 (15.7) 
Total 63(58.3) 45 (41.7) 108(100.0) 
* Calculated for chi-square 
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4. Discussion 
In the present study, the HBV vaccination cov-
erage rate among malnourished Yemeni chil-
dren was 89.3%. This finding is higher than that 
(69.9%) of a previous study conducted by Al-
Shamahy et al. (9) on healthy children in Sana'a. 
This difference may possibly be due to the dif-
ference in the times at which the two studies 
were conducted and to the enhanced response 
to the Ministry of Public Health and Population 
calls (educational programs and vaccination 
campaigns). In general, the health status has 
greatly improved in Yemen over the years due 
to better socio-economic levels, educational 
status and health awareness. However, the find-
ing of the present study is lower than those re-
ported from other HBV endemic countries, 
where HBV vaccine coverage rates among chil-
dren ranged from 90–98% (30, 31). 
In this study, there was a significant differ-
ence in protection rate at the various annual 
intervals (1–5 years) since vaccination in two 
studies; annual titer reduction in children un-
der seven years old was 10.2% (13). Zhou et al. 
(32) reported that protective levels of antibod-
ies decrease with time. Furthermore, a recent 
study showed that in healthy Yemeni people, 
the levels of anti-HBs antibodies decreased 
with time (9). Increasing age was correlated 
with a decreasing level of protection rate. The 
response rate of anti-HBs declined from 86.1% 
in the ˂ one-year age group to 23.1% in > 4–5-
year age groups. This result is similar to those 
of other studies conducted in Yemen (9), Saudi 
Arabia (33), China (34) and Europe (35). Im-
munosenescence as a result of continuous im-
mune response deterioration results in a de-
creased response to vaccines. Decrease in de 
novo production of B and T cells is a well-
described alteration related to increasing age. 
In addition, the memory cell accumulation and 
loss of diversity in antigen specificities due to a 
lifetime of exposure to pathogens have also 
been described (36). 
The mean anti-HBs level in the present 
study was 304.54 IU/L, and the rate of seropro-
tection was 72.2%. Such rate is lower than that 
reported by Sallam et al. (11) in a study con-
ducted in Sana’a, where 83.5% of healthy chil-
dren were with anti-HBs seroprotective levels 
(11). However, the seroprotective rate in the 
present study is higher than that (54.8%) 
among healthy children in Sana’a (9). Variable 
seroprotective rates have been reported from 
different countries; 96.7% in Turkey (37), 86% 
in Taiwan (38), 57.2% in Egypt (39) and 41% in 
the United States (40). 
In our study, nutritional status was found to 
affect anti-HBs levels, with a significant associa-
tion between anti-HBs levels and the severity of 
malnutrition. This is similar to other studies. 
For instance, Rey et al. (41) found that nutri-
tional status was significantly associated with 
response to HBV vaccination in Senegal and 
Cameroon, where 85% of children with normal 
nutritional status were protected (anti-HBs ≥10 
IU/L) versus 60% with moderate to severe 
malnutrition. In Iran, Karimi et al. (42) found a 
significant decrease in the immune response to 
HBV vaccine in malnourished children (60.2%) 
and that severe acute malnutrition produced a 
higher protective immune response than mod-
erate acute malnutrition. Losonsky et al. (43) 
concluded that low and poor weight gains in the 
first 6 months of life were associated with re-
duced immunogenicity (71%) following three 
doses of HBV vaccine in the United States. Wang 
(44) reported that the response to HBV vaccine 
in low socio-economic areas was low in Taiwan. 
Experimentally, rats with PEM were found not 
to respond to HBV vaccination in comparison to 
control rats. In a histopathology study, PEM 
was found to cause a decrease in dendritic cells 
and their stimulatory functions on T cells (45). 
Aria et al. (46) showed a negative effect of mal-
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nutrition, immune deficiency and drug addic-
tion on HBV vaccine immune response. In a 
similar fashion, antibody responses to H. influ-
enzae type b conjugate vaccine was found to be 
lower in Kenyan children with stunting and 
chronic malnutrition than those in well-
nourished infants (47). These contradictory 
findings on survival of vaccine can be due to 
ethnic differences or non-apparent exposure to 
HBV in endemic areas. 
 A descriptive study conducted by Cha-
rareewong et al. (48) on 25 premature infants 
showed the seroconversion rate was high 88%. 
El-Jamal et al. (49) reported a 100% protection 
rate among Egyptian healthy infants two 
months after the last HBV vaccine dose com-
pared to 87% among protein energy malnour-
ished ones; however, the difference was not 
significant. However, Muhammad et al. (50) 
concluded that the nutritional status had no 
effect on the immune response of infants to 
HBV vaccine. These differences stress the ne-
cessity for further studies with larger sample 
sizes and consideration of possible factors such 
as age, sex, race, site of injection, nutritional 
status and vaccine brand. Obesity is a type of 
malnutrition, and some studies showed that 
obesity was a predicting factor for a weak re-
sponse to HBV vaccine (51, 52). Frequent stud-
ies investigated the effect of malnutrition on 
response to HBV vaccine in hemodialysis pa-
tients. The impact of malnutrition on serocon-
version has been shown (51). We postulate that 
malnutrition in under five-year-old children 
cannot prevent a competent immune response 
to HBV vaccine but may reduce such response. 
Similar to our findings were reported in a study 
conducted in Guatemala (53). 
 
5. Conclusions 
A good HBV vaccine coverage rate was 
found among malnourished Yemeni children, 
with a moderate rate of protection. This indi-
cates that nutritional status affects the immune 
response to HBV vaccine and seroprotection 
rate. Although these results are for malnutrition 
as a whole, our small sample size makes it im-
possible to conclude definitively on the severity 
of malnutrition and impact on the immune re-
sponse. Therefore, further research with a larg-
er sample size and case-control studies are re-
quired. Re-vaccination or administration of 
booster doses to a substantial proportion of 
vaccinated children in Yemen should be consid-
ered. 
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